Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Haematologica. Open access journal of the Ferrata-Storti Foundation, a no profit organization
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
  • Home
  • Current Issue
  • Early view
  • Review Series
  • Archive
  • About Us
    About Haematologica Editorial Team Our Policies Advertising Rights & Permissions Contact
  • Haematologica Award
    How to participate 2025 Winners
  • Submit a Manuscript
    Author Guidelines Reviewer Guidelines Submit and Track Manuscript Track Manuscript submitted before October 1st, 2025
Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Search results are limited to:
Abstract Book of the 7th European Myeloma Network Meeting, Prague, 16-18 April 2026
Vol. 111 No. s2
Advanced filters
Search the full archive

B09 | DARATUMUMAB MONOTHERAPY VS. ACTIVE MONITORING IN PATIENTS WITH HIGH-RISK SMOLDERING MULTIPLE MYELOMA: "AQUILA" OUTCOMES BASED ON MAYO 2018/IMWG 2020 RISK STRATIFICATION, IMWG 2020 PLUS CYTOGENETIC CRITERIA, AND AGE (453 Online Views)

F. Schjesvold1, P.M. Voorhees2, M.A. Dimopoulos3, Y.C. Cohen4, V. Hungria5, I. Sandhu6, J. Lindsay7, R.I. Baker8, K. Suzuki9, H. Kosugi10, M-D. Levin11, M. Beksac12, K. Stockerl-Goldstein13, H. Magen4, A. Oriol14|15, G. Mikala16, G. Garate17, K. Theunissen18, I. Spicka19, A.K. Mylin20, S. Hallam21, S. Bringhen22, K. Uttervall23, B. Pula24, A.M. Khan25, E. Medvedova26, J.C. Ye27, A.J. Cowan28, P.. Moreau29, M-V. Mateos30, H. Goldschmidt31, D. Vieyra32, A. Raval32, L. Sha32, L. Li32, E. Rousseau32, R.M. Dennis32, R.L. Carson32, S.V. Rajkumar33

1 University of Oslo, Norway
2 Wake Forest University School of Medicine, Charlotte, USA
3 National and Kapodistrian University of Athens, Greece
4 Tel Aviv University, Israel
5 Clinica Médica São Germano, São Paulo, Brazil
6 Cross Cancer Institute, Edmonton, Canada
7 Kent and Canterbury Hospital, Canterbury, UK
8 Murdoch University, Perth, Australia
9 Japanese Red Cross Medical Center, Tokyo, Japan
10 Ogaki Municipal Hospital, Japan
11 Albert Schweitzer Hospital, Dordrecht, The Netherlands
12 Ankara University, Turkey
13 Washington University School of Medicine, St. Louis, USA
14 Hospital Germans Trias i Pujol
15 , Badalona, Spain
16 South Pest Central Hospital, Budapest, Hungary
17 Hospital Alemán, Buenos Aires, Argentina
18 Jessa Hospital, Hasselt, Belgium
19 Charles University, Prague, Czech Republic
20 University of Copenhagen, Denmark
21 Queen Mary University of London, UK
22 AOU Città della Salute e della Scienza di Torino, Italy
23 Karolinska University Hospital, Stockholm, Sweden
24 Institute of Hematology and Transfusion Medicine, Warsaw, Poland
25 The Ohio State University Comprehensive Cancer Center, Columbus, USA
26 Oregon Health and Science University, Portland, USA
27 University of Texas, Houston, USA
28 University of Washington, Seattle, USA
29 University Hospital Hôtel-Dieu, Nantes, France
30 University Hospital of Salamanca, Spain
31 Heidelberg University Hospital, Germany
32 Johnson & Johnson
33 Mayo Clinic, Rochester, USA
Smoldering Multiple Myeloma AQUILA study Daratumumab.

P37 | ANALYSIS OF PATIENTS WITH PRIOR BCMA-TARGETED THERAPY AND THOSE ACHIEVING COMPLETE RESPONSE IN REALiTAL: A MULTI-COUNTRY OBSERVATIONAL STUDY OF TALQUETAMAB IN RELAPSED/REFRACTORY MULTIPLE MYELOMA OUTSIDE OF CLINICAL TRIALS (369 Online Views)

R. Popat1, K.M. Kortüm2, H. Magen3, V. Mykytiv4, C. Liberatore5, E. Zamagni6, M.C. Da Vià7, E. Antonioli8, M. Hansson9, D. Santra10, D. Greer10, K. Subrt11, P. Hu11, E. Aeby11, N. Francella11, N.M. Suñe11, A. Perrot12, K. Uttervall13

1 University College London Hospitals NHS Foundation Trust, UK
2 University Hospital of Würzburg, Germany
3 Tel Aviv University, Israel
4 Cork University Hospital, Ireland
5 Ospedale Santo Spirito, Pescara, Italy
6 University of Bologna, Italy
7 IRCCS Fondazione Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy
8 Careggi Hospital and University of Florence, Italy
9 Sahlgrenska University Hospital, Gothenburg, Sweden
10 Parexel International
11 Johnson & Johnson
12 Université de Toulouse, France
13 Karolinska University Hospital, Stockholm, Sweden
Multiple Myeloma REALiTAL Trial RRMM

P41 | FIRST RESULTS OF REALiTEC-2: SECOND COHORT OF REALiTEC, AN INTERNATIONAL OBSERVATIONAL RETROSPECTIVE STUDY OF TECLISTAMAB IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA IN ROUTINE CLINICAL PRACTICE (336 Online Views)

R. Popat1, K. Uttervall2, K.M. Kortüm3, H. Magen4, M. Hansson5, T. Shragai6, E. Terpos7, C. T. Hansen8, S. Manier9|10, H. Gregersen11, Ø.M. Ottestad12, C. Touzeau13, E. Hatjiharissi14|15, S.L. Farmer16, E. Katodritou17, E. Spanoudakis18, M.Ø. Vase19, C. Liberatore20|21, M. Papathanasiou22, M.K. Angelopoulou7|23, E. Clavero24, R. Kittus25, P. Smirnov25, P. Hu25, D. Santra26, C. Albrecht25, E. Rubio-Azpeitia25, A. Perrot27

1 University College London Hospitals NHS Foundation Trust, UK
2 Karolinska University Hospital, Stockholm, Sweden
3 University Hospital of Würzburg, Germany
4 Tel-Aviv University, Israel
5 Sahlgrenska University Hospital, Gothenburg, Sweden
6 Tel-Aviv Sourasky Medical Center, Israel
7 National and Kapodistrian University of Athens, Greece
8 Odense University Hospital, Denmark
9 University of Lille, France
10 Centre Hospitalier Universitaire Lille, France
11 Aalborg University Hospital, Denmark
12 Akershus University Hospital, Lørenskog, Norway
13 University Hospital Hôtel-Dieu, Nantes, France
14 AHEPA University Hospital, Thessaloniki, Greece
15 Aristotle University of Thessaloniki, Greece
16 Vejle Hospital, Denmark
17 Theagenio Cancer Hospital, Thessaloniki, Greece
18 Democritus University of Thrace, Alexandroupolis, Greece
19 Aarhus University Hospital, Denmark
20 Santo Spirito Hospital, Pescara, Italy
21 "G d'Annunzio" University, Chieti, Italy
22 G Papanicolaou Hospital, Thessaloniki, Greece
23 Laiko General Hospital, Athens, Greece
24 Hospital Universitario Virgen De Las Nieves, Granada, Spain
25 Johnson and Johnson
26 Parexel International on behalf of Johnson & Johnson, Sheffield, UK
27 Université de Toulouse, France
REALiTEC-2 Trial RRMM Teclistamab

P42 | COMPARATIVE EFFECTIVENESS OF TECLISTAMAB IN REALiTEC VS. REAL-WORLD PHYSICIAN’S CHOICE OF THERAPY IN LOCOMMOTION AND MOMMENT IN TRIPLE-CLASS EXPOSED RELAPSED AND REFRACTORY MULTIPLE MYELOMA (237 Online Views)

A. Perrot1, M. Kortüm2, R. Popat3, K. Uttervall4, M.V. Mateos5, K. Weisel6, K. Van Nimwegen7, J. Diels7, F. Ong7, R. Morano7, E. Rubio-Azpeitia7, P. Moreau8

1 Universite de Toulouse, France
2 University Hospital of Würzburg, Germany
3 University College London Hospitals NHS Foundation Trust, UK
4 Karolinska University Hospital, Stockholm, Sweden
5 Hospital Universitario de Salamanca, Spain
6 University Medical Center Hamburg-Eppendorf, Hamburg, Germany
7 Johnson & Johnson
8 University Hospital Hôtel-Dieu, Nantes, France
Multiple Myeloma RRMM Teclistamab
Loading...
Searching...
1 - 4 of 4 items
Navigate
  • Home
  • Current issue
  • Early view
  • Archive
  • About Haematologica
  • Editorial Team
  • Our policies
  • Contact
For Authors
  • Author Guidelines
  • Submit Manuscript
  • Track Manuscript
For Reviewers
  • Reviewer Guidelines
  • Access Your Profile
  • Access Your Tasks
For Advertisers
  • Information For Advertising
Education
  • Review Articles
  • Guidelines Articles
Privacy
  • Cookie Policy
  • Newsletter Privacy Policy
  • Privacy Policy
More
  • Rights & Permissions

  • Web design
  • Development
Copyright © 2026 by the Ferrata Storti Foundation | Web design → | Development →
ISSN 0390-6078 print | ISSN 1592-8721 online